A Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Subjects With Hemophilia A Or B

Inclusion Criteria:

- Male subjects 18 to <65 years old with severe hemophilia A or B with or without
inhibitors to FVIII or FIX.

- Subjects is willing and able to comply with the mandatory washout periods prior to
screening and prior to dosing and through 48 hours post dosing. At screening this
includes a washout of FIX for 96 hours and FVIII for 72 houts. At dosing this
includes a washout of FIX for 96 hours and FVIII and other hemostatic agents for 72
hours through 48 hours post dosing.

- Subjects must agree and commit to using a a highly effective method of birth control
from the time of screening through four weeks after study drug administration.

Exclusion Criteria:

- Presence of a bleeding disorder in addition to hemophilia A or B.

- Regular, concomitant therapy with immunomodulating drugs (eg, intravenous
immunoglobulin, and routine systemic corticosteroids).

- History of coronary artery disease, thrombolic disease or diagnosis of prothrombic
disorder.